# A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

> **NCT00034775** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 141 (actual)

## Conditions studied

- Schizophrenia
- Psychotic Disorders

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00034775
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2002-10
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2011-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034775, "A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00034775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*